You are adding an alert for:
Comparing intravitreal bevacizumab, sub threshold macular laser (STML) and intravitreal dexamethasone implant (0.7mg) in the initial treatment of diabetic macular edema (DME) in a resident led clinic.
You will receive an email whenever this article is corrected, updated, or cited in the literature. You can manage this and all other alerts in My Account
The alert will be sent to: